Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production.

Guo Y, Fan Y, Zhang J, Lomberk GA, Zhou Z, Sun L, Mathison AJ, Garcia-Barrio MT, Zhang J, Zeng L, Li L, Pennathur S, Willer CJ, Rader DJ, Urrutia R, Chen YE. Perhexiline activates KLF14 and reduces atherosclerosis by modulating ApoA-I production. J Clin Invest. 2015 Oct 01; 125(10):3819-30.

View in: PubMed

subject areas

Animals
Apolipoprotein A-I
Apolipoproteins E
Atherosclerosis
Cholesterol
Cholesterol, HDL
Diet, Atherogenic
Drug Evaluation, Preclinical
Gene Expression Regulation
Genetic Vectors
Genome-Wide Association Study
Hep G2 Cells
Humans
Hyperlipoproteinemia Type II
Kruppel-Like Transcription Factors
Leptin
Liver
Mice
Mice, Inbred C57BL
Mice, Obese
Perhexiline
Recombinant Fusion Proteins
RNA, Messenger
Sp Transcription Factors
Sterol Regulatory Element Binding Proteins

RCMI CC is supported by the National Institute on Minority Health and Health Disparities, National Institutes of Health (NIH), through Grant Number U24MD015970. The contents of this site are solely the responsibility of the authors and do not necessarily represent the official views of the NIH

For technical support please contact support